Trial Profile

Multicenter, Open-label, Phase 1 Study of Allo-RevCAR01-T-CD123 Consisting of Genetically Modified T Cells Carrying Reverse Chimeric Antigen Receptors (Allo RevCAR01 T) in Combination With CD123 Target Module (R-TM123) for the Treatment of Patients With Selected Hematologic Malignancies Positive for CD123

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 23 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AVC 201 (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary)
Indications Acute myeloid leukaemia; Haematological malignancies
Focus Adverse reactions
Sponsors AvenCell Europe

10 Feb 2025 Planned number of patients changed from 37 to 80.
10 Feb 2025 Planned End Date changed from 1 Jun 2026 to 1 Jan 2028.
10 Feb 2025 Planned primary completion date changed from 1 Dec 2025 to 1 May 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com